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CASE REPORT
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ABSTRACT
Idiopathic intracranial hypertension (IIH), a condition of raised intracranial pressure, is charac-
terised by headaches and visual disturbances. Its pathogenesis is currently unknown; however,
dysregulation of androgens may be implicated. Here, the authors present a case of a 22-year-old
patient undergoing female-to-male (FTM) gender reassignment who developed IIH shortly after
commencing testosterone therapy. This interesting case presents the possibility of androgens
having a pathogenic role in IIH.
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Idiopathic intracranial hypertension (IIH) is a dis-
order of raised intracranial pressure (ICP), typi-
cally presenting with headaches, papilloedema, and
visual loss. Headaches can be severe, causing sig-
nificant morbidity, although there is increasing
recognition of the variability in their presentation.1
There is also a recognised subset of patients where
papilloedema is not present, IIH without papilloe-
dema (IIHWOP).2 The condition has a predilec-
tion for obese women of childbearing age,3 yet the
reasons for this are not clear.4
A condition with similar phenotypic character-
istics of obese, young women is polycystic ovary
syndrome (PCOS). Androgen excess is a defining
feature of PCOS.5 There is an increased prevalence
of PCOS in the IIH population, with reports of up
to 57% of IIH patients also having PCOS,6 com-
pared with a prevalence of 5–10% in the general
population.7 It is interesting to speculate that IIH,
akin to PCOS, could be driven by androgen excess.
In support of this, a study has found that
hyperandrogenism is linked with younger age of
onset of IIH but is not associated with body mass
index (BMI), waist-to-hip ratios, or duration of
IIH.8
Karyotypically female patients undergoing
female-to-male (FTM) gender reassignment with
testosterone therapy offer an important opportunity
to increase our understanding of the role of andro-
gens in IIH. Here, we present the case of a patient
undergoing gender reassignment who developed IIH
on commencing testosterone therapy.
Case report
A 22-year-old karyotypically 46XX patient under-
going FTM gender reassignment presented with a
6-month history of new daily headaches and 5
months of intermittent visual blurring, pulsatile
tinnitus, and nausea. He had started testosterone
injections (250 mg 3-monthly) just prior to symp-
tom onset (Figure 1). His visual symptoms pro-
gressed, and he began to develop transient visual
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obscurations up to 50 times per day. He presented
to his opticians, who noted bilateral papilloedema
and referred him to neuro-ophthalmology. Best-
corrected visual acuity was 6/9 bilaterally, Ishihara
colour vision was normal, and there was no rela-
tive afferent pupillary defect (RAPD). He was con-
firmed to have severe bilateral papilloedema,
modified Frisén grade 3 in the right eye and
grade 4 in the left eye,9 with no sixth nerve palsy.
Spectral-domain optical coherence tomography
was performed (Figure 2), and the overall maxi-
mum retinal nerve fibre layer (RNFL) height was
1226 μm for the left eye and 1218 μm for the right
eye. Goldmann visual fields showed bilateral
increase in the blind spot, loss of some static
central points in the right eye, with the left eye
showing an increased nasal step. Magnetic reso-
nance (MR) imaging of the brain (Siemens 3.0
Tesla) showed a partial empty sella on T2-
weighted imaging, and MR venography demon-
strated no cerebral sinus thrombosis. Two lumbar
punctures a few days apart recorded opening pres-
sures of 40 and 39 cm cerebrospinal fluid (CSF).
Although he was classed as overweight on starting
testosterone injections (BMI 27.9 kg/m2), his
weight had only increased over the period of the
testosterone therapy to a very small degree (+3.3
kg in 6 months). His full blood count, renal and
liver functions, and inflammatory markers were
normal. His regular medications consisted of reg-
ular pain relief with codeine and naproxen, zopi-
clone 7.5 mg, sertraline 50 mg OD, desogestrel 75
μg (for suppression of menses and endometrial
protection), and 3-monthly testosterone injections
(250 mg). There was no evidence of other second-
ary cause of raised ICP. Due to emergent dete-
rioration in visual function, he was referred for
CSF diversion with a lumbo-peritoneal shunt.
Following lumbo-peritoneal shunt insertion,
papilloedema settled. The patient decided to con-
tinue testosterone injections; the testosterone
Figure 1. Profile of serum testosterone over time since initia-
tion of therapy, with first presentation at 6 months.
Figure 2. Composite figure showing colour fundus photographs of the papilloedema affecting the optic nerve head (OHN) of the
right (A) and left (C) eyes. Optical coherence tomography (OCT) SPECTRALIS HRA+OCT (Heidelberg Engineering, Heidelberg,
Germany), infrared (IR) images of the ONH, and volume cross-sectional images and the elevated height through the centre of the
ONH of the right (E) and left (F) eyes. OCT IR disc volume reconstructions for right (B) and left (D) eyes.
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levels remained elevated (Figure 1) and his weight
remains stable. At 18 months post shunt insertion,
the IIH remained in remission and he went on to
have a bilateral mastectomy.
Discussion
This case is unusual, as it reports the development
of IIH in a transgender patient on testosterone
therapy. The temporal relationship of initiation
of testosterone therapy and the onset of symptoms
in this case may suggest a link between raised
intracranial pressure and testosterone. However,
this occurrence is not in isolation, as four other
reports in the literature document similar cases of
IIH arising in patients undergoing gender reas-
signment with testosterone therapy, with three
having a temporal relationship with commencing
testosterone therapy.10,11,13 All cases reported were
reassigning their gender from female to male
(Table 1).
Transgender patients who develop IIH provide
an insight into the potentially pathogenic role of
testosterone in IIH. The predilection of the disease
for a particular gender would suggest that hor-
mones may play a role in pathogenesis; however,
previous studies into the role of oestrogens were
inconclusive and have not been replicated.14,15 It
may be that the class of hormones that need
further investigation are the androgens, as high-
lighted by this case report and the previous cases
(Table 1), coupled with the observation that
another androgen dysregulated condition, PCOS,
shares a strikingly similar clinical phenotype.
Furthermore, one study reports an increased inci-
dence (58%) of PCOS in FTM patients prior to
hormonal therapy.16 It is notable that IIH has also
been reported in men with hypogonadism, with
cases described in men after androgen deprivation
therapy for prostate cancer.17 Additionally, men
with IIH are more likely to have symptoms asso-
ciated with testosterone deficiency.18 This raises
the prospect of a “pathophysiological window” of
circulating testosterone levels in humans, with
levels above the normal reference range for
females, but below the normal reference range
for men, associated with metabolic perturbations,
including increased visceral fat deposition, insulin
resistance, and fatty liver disease.19 Serum testos-
terone levels in the cases described above were
within this window when first presentation
occurred. It is therefore feasible that IIH is a dis-
tinct neuro-metabolic complication of circulating
testosterone levels within this range. These obser-
vations present an interesting avenue for new
research in IIH and warrant the need for further
detailed characterisation of the androgen meta-
bolic phenotype in this condition.
Table 1. Summary of cases IIH in gender reassignment in the literature to date.
Author Year
Gender
reassignment Symptom occurrence
Testosterone
temporally
causative
Body mass index
(kg/m2) Treatment Outcome
Case presented 2017 FTM Symptoms correlate with
testosterone commencing
Yes 27.9 LP shunt Remission
of raised
intracranial
pressure
Buchanan
et al.11
2017 FTM Increasing dose of
testosterone, and increased
weight
Yes Not known Treatment was initially
reducing testosterone
hormone therapy by 50%
and acetazolamide. Then
subsequent weight loss
Remission
Park et al.13 2014 FTM Patient was on testosterone Yes Not known Swapped to longer-acting
testosterone therapy and
started acetazolamide
Remission
Mowl et al.10 2009 FTM Patient was on testosterone Yes 27 Reducing testosterone
therapy and Diamox
Remission
Sheets et al.12 2007 FTM Symptoms started 10
months after discontinuing
testosterone
No 29.8 Initially acetazolamide, due
to side effects switched to
frusemide and topiramate.
Subsequent unilateral optic
nerve sheath fenestration
Remission
NEURO-OPHTHALMOLOGY 3
Declaration of interest
The authors report no conflicts of interest. The authors alone
are responsible for the content and writing of the article.
Funding
C.H. is funded by an intercalating student award from the
Association of British Neurologists. A.S. is funded by an
NIHR Clinician Scientist Fellowship (NIHR-CS-011-028)
and by the Medical Research Council, UK (MR/K015184/1).
ORCID
Catherine Hornby http://orcid.org/0000-0003-2218-9695
References
[1] Yri HM, Wegener M, Sander B, Jensen R. Idiopathic
intracranial hypertension is not benign: a long-term
outcome study. J Neurol 2012;259:886–894.
[2] Marcelis J, Silberstein SD. Idiopathic intracranial
hypertension without papilledema. Arch Neurol
1991;48:392–399.
[3] Mollan SP, Ali F, Hassan-Smith G, Botfield H,
Friedman DI, Sinclair AJ. Evolving evidence in adult
idiopathic intracranial hypertension: pathophysiology
and management. J Neurol Neurosurg Psychiatry
2016;87:982–992.
[4] Markey KA, Mollan SP, Jensen RH, Sinclair AJ.
Understanding idiopathic intracranial hypertension:
mechanisms, management, and future directions.
Lancet Neurol 2016;15:78–91.
[5] Franks S. Polycystic ovary syndrome. N Engl J Med
1995;333:853–861.
[6] Glueck CJ, Aregawi D, Goldenberg N, Golnik KC,
Sieve L, Wang P. Idiopathic intracranial hypertension,
polycystic-ovary syndrome, and thrombophilia. J Lab
Clin Med 2005;145:72–82.
[7] Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer
ES, Yildiz BO. The prevalence and features of the
polycystic ovary syndrome in an unselected popula-
tion. J Clin Endocrinol Metab 2004;89:2745–2749.
[8] Klein A, Stern N, Osher E, Kliper E, Kesler A.
Hyperandrogenism is associated with earlier age of
onset of idiopathic intracranial hypertension in
women. Curr Eye Res 2013;38:972–976.
[9] Scott CJ, Kardon RH, Lee AG, Frisen L, Wall M.
Diagnosis and grading of papilledema in patients with
raised intracranial pressure using optical coherence
tomography vs clinical expert assessment using a clin-
ical staging scale. Arch Ophthalmol 2010;128:705–711.
[10] Mowl AD, Grogg JA, Klein J. Secondary pseudotumour
cerebri in a patient undergoing sexual reassignment
therapy. Clin Exp Optom 2009;92:449–453.
[11] Buchanan I, Hansen K, Bedolla J. Idiopathic intracra-
nial hypertension in a transgender male on hormone
therapy. Arch Emerg Med Crit Care 2017;2:1019.
[12] Sheets C, Peden M, Guy J. Idiopathic intracranial
hypertension in a transgender man. J
Neuroophthalmol 2007;27:313–315.
[13] Park S, Cheng CP, Lim LT, Gerber D. Secondary intra-
cranial hypertension from testosterone therapy in a trans-
gender patient. Semin Ophthalmol 2014;29:156–158.
[14] Donaldson JO, Horak E. Cerebrospinal fluid oestrone
in pseudotumour cerebri. J Neurol Neurosurg
Psychiatry 1982;45:734–736.
[15] Soelberg Sorensen P, Gjerris F, Svenstrup B. Endocrine
studies in patients with pseudotumor cerebri. Estrogen
levels in blood and cerebrospinal fluid. Arch Neurol
1986;43:902–906.
[16] Baba T, Endo T, Honnma H, Kitajima Y, Hayashi T,
Ikeda H, Masumori N, Kamiya H, Moriwaka O, Saito
T. Association between polycystic ovary syndrome and
female-to-male transsexuality. Hum Reprod
2007;22:1011–1016.
[17] Valcamonico F, Arcangeli G, Consoli F, Nonnis D,
Grisanti S, Gatti E, Berruti A, Ferrari V. Idiopathic
intracranial hypertension: a possible complication in
the natural history of advanced prostate cancer. Int J
Urol 2014;21:335–337.
[18] Fraser JA, Bruce BB, Rucker J, Fraser LA, Atkins EJ,
Newman NJ, Biousse V. Risk factors for idiopathic
intracranial hypertension in men: a case-control
study. J Neurol Sci 2010;290:86–89.
[19] Hazlehurst JM, Oprescu AI, Nikolaou N, Di Guida R,
Grinbergs AE, Davies NP, Flintham RB, Armstrong
MJ, Taylor AE, Hughes BA, Yu J, Hodson L, Dunn
WB, Tomlinson JW. Dual-5alpha-reductase inhibition
promotes hepatic lipid accumulation in man. J Clin
Endocrinol Metab 2016;101:103–113.
4 C. HORNBY ET AL.
